A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.

Trial Profile

A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications Cancer; Cutaneous T cell lymphoma; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors argenx
  • Most Recent Events

    • 08 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
    • 08 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 04 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top